Perflenapent/Perflisopent

全氟戊烷/全氟异戊烷

Report date: 2022/03/04 16:16:40

Base Information

Drug NamePerflenapent/Perflisopent
Drug Alias NamePerflisopent/Perflenapent全氟异戊烷/全氟戊烷EchoGenFC-4112QW-3600
ClassificationSmall molecules
Mechanisms of ActionUltrasonography enhancers
TargetsNot applicable
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Perflenapent
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSonus Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSonus Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A